ImaBiotech specializes in providing advanced mass spectrometry imaging services to enhance drug development processes. The company serves pharmaceutical and biotechnology clients by offering solutions in biomarker discovery, drug metabolism and pharmacokinetics (DMPK), pharmacology, toxicity, and ADME (absorption, distribution, metabolism, and excretion) studies. Operating in the preclinical and clinical research markets, ImaBiotech leverages cutting-edge technologies such as quantitative mass spectrometry imaging, cloud computing, big data, and machine learning to deliver precise and cost-effective solutions. The business model revolves around offering specialized analytical services that support drug development from lead optimization to Phase III clinical trials. Revenue is generated through service contracts with pharmaceutical companies, research institutions, and biotech firms. ImaBiotech's innovative platforms include molecular imaging, elemental imaging, and laser microdissection, with a capacity to perform over 2,500 biomarker assays. The company has a strong focus on therapeutic areas such as oncology, dermatology, ophthalmology, respiratory diseases, central nervous system disorders, and metabolic disorders. Founded by Jonathan Stauber, PhD, ImaBiotech has received numerous awards, underscoring its commitment to scientific advancement and industry growth.

Keywords: mass spectrometry imaging, drug development, biomarker discovery, pharmacology, DMPK, ADME, oncology, dermatology, biotechnology, clinical trials.